We compared outcome and toxicity in two paediatric groups undergoing SCT and treated with busulphan (BU) by the oral route of administration. One group receiving the standard dose of 1 mg/kg q.i.d. for a total of 16 doses was compared with age-and disease-matched patients receiving 2 mg/kg of BU b.i.d. for a total of eight doses. Seventy-two patients from two Swedish paediatric transplantation centres were included; one centre used a standard q.i.d. administration (n ¼ 37) and the second centre used a b.i.d. administration setting (n ¼ 35). Our primary objective was to determine the incidence of veno-occlusive disease (VOD), graft-versus-host disease (GVHD), relapse frequency and transplant-related mortality in both cohorts. A total of 17 autologous and 55 allogeneic transplantations was performed for malignant (n ¼ 47) and non-malignant (n ¼ 25) diseases in the two centres during the period 1990-2005. No significant difference in the incidence of VOD, graft rejection, GVHD, relapse rate or overall survival was observed between the two centres. The clinical outcome of SCT for paediatric patients conditioned with oral BU at a dose of 2 mg/kg for eight doses is comparable to that found for children conditioned using the standard regimen given 1 mg/kg q.i.d. for 16 doses.
Introduction
Oral busulphan (BU) is an alkylating agent that has been used for myeloablation of patients undergoing SCT since the early 1980s. The standard dose of BU for both adults and children is 1 mg/kg administered orally every 6 h for 16 doses (total dose 16 mg/kg). Since standard dose results in a large variability of exposure to the drug between patients, many centres use drug monitoring with adjustment of the dose to achieve a defined area under the curve (AUC).
BU is metabolized in the liver through conjugation with glutathione, an enzymatic reaction that involve glutathione S-transferase. The metabolites undergo multiple pathways and are excreted via the bile or urine. 1 It has been proposed that genetic polymorphisms of glutathione S-transferase might influence BU pharmacokinetics and thereby the incidence of veno-occlusive disease (VOD). 2, 3 As for most of the alkylating agents, the therapeutic window of BU is narrow and factors such as age, obesity, circadian rhythm and bioavailability influence pharmacokinetics. 4 Therefore, drug monitoring with subsequent dose adjustment is performed in several centres. Several pharmacokinetic models for monitoring the BU concentration have been proposed. [4] [5] [6] [7] [8] At present, most centres in Sweden use a limited sampling model based on three samples measured after the first dose. The AUC obtained is then used for dose adjustment of subsequent BU doses. 8 The model parameters include liver function, weight and phenytoin treatment. The model has been tested and evaluated both for the four-dose administration of 1 mg/kg bodyweight and for the two-dose regimen of 2 mg/kg bodyweight. 9 Low concentrations of BU are reported to be associated with graft rejection in children 10 and a high relapse rate in adult patients. 11, 12 Moreover, high concentrations have been reported to correlate with severe regimen-induced toxicity such as VOD, interstitial pneumonitis and convulsions. [13] [14] [15] However, some studies have failed to find an association between the concentration of BU and the incidence of VOD. 16 Since the two largest paediatric stem cell transplant centres in Sweden use different BU regimens, we investigated and compared the toxicity and efficacy of four-dose (BU4) and two-dose BU (BU2), in two age-and disease-matched cohorts treated at the respective centres.
Patients and methods

Patients characteristics
Thirty-seven (BU4) and 35 (BU2) age-and disease-matched paediatric patients from each of the two centres were included. All patients were transplanted during the period 1990-2005. All BU concentrations were analysed at the same laboratory for all patients. Data concerning AUC, patient characteristics and outcome were collected retrospectively.
One centre used standard four-times-a-day administration of 1 mg/kg (BU4) and the second centre used a conditioning based on twice-daily administration of 2 mg/ kg BU2. BU doses were given orally as a combination of gelatine capsules (25 and 10 mg) and tablets of 2 mg. The dose was calculated according to actual body weight and adjusted after the third dose in both BU2 and BU4 groups to achieve a target AUC during the conditioning period of 4800-5500 ng/ml Â h in the four dose (BU4) and 9600-11 000 ng/ml Â h in the two dose (BU2) regimen. All patients received all prescribed doses, i.e., eight doses in BU2 and 16 doses in BU4. The limited sampling model with dose adjustment was introduced in 1998 in Sweden and around 50% of the doses in each of the centres have been adjusted to reach target levels.
Median age was 5 years in the BU4 cohort and 2.9 years in the BU2 cohort ( Table 1) . The difference in age between the groups was not statistically significant. There were four infants (o1 year at time of SCT) in the BU4 cohort and seven in the Bu2 cohort.
Eight versus nine autologous and 29 versus 26 allogeneic transplantations were performed in the BU4 group and the BU2 group, respectively. Transplant indications were leukaemia (ALL, AML, CML and JMML (juvenile myelomonocytic leukaemia)) in 32 patients, solid tumours (neuroblastoma, lymphoma) in 15 patients and nonmalignant diseases (immunodeficiencies, familial haemophagocytic lymphoproliferative, aplastic anaemia and metabolic) in 25 patients with an equal distribution of patients between the two centres.
Conditioning regimen consisted of BU/cyclophosphamide (CY) ± antithymocyte globulin in 52 patients, BU/ CY/melphalan in seven patients, BU/CY/etoposide in two patients, BU/fludarabine/antithymocyte globulin in one patient, BU/melphalan in eight patients and BU/thiothepa/ CY/antithymocyte globulin in two patients. The combination of BU and CY was used in 36/37 patients in the BU4 cohort and in 27/35 patients in the BU2 cohort. Patient data are summarized in Table 1 . During BU treatment, all patients received clonazepam orally as prophylactic treatment for seizures, starting the day before administration of BU.
Diagnosis of VOD
Veno-occlusive disease was diagnosed on the basis of Jones criteria: 17 hyperbilirubinaemia with serum bilirubin level greater than 34 mmol/l, and any two of the following symptoms: ascites, painful hepatomegaly and unexplained weight gain X5% from baseline within 20 days of BMT. Liver biopsies were only rarely performed for diagnostic purposes. VOD was not graded in this study.
Limited sampling model for BU concentration determination Patient outcome as defined by disease-free survival (DFS) and overall survival (OS), and the frequency of VOD, were analysed and BU plasma concentration expressed as AUC was determined. To estimate AUC for the first dose, a limited sampling model based on three concentration time points (1, 3 and 6 h) was used for both cohorts. This model has earlier been described in detail. 8 The dose adjustment based on the first dose concentrations was introduced in 1998 in both the centres.
Statistical analysis
Patient status was determined as of March 2006. DFS and OS are reported as calculated values at 5 years ± s.e.m. DFS is defined as the time from SCT to relapse, death in remission from any cause or the date of last follow-up visit (censored time). Death from any cause was the event in survival analysis. DFS and OS curves were calculated using Kaplan-Meier plots. 18 The Mann-Whitney rank test was used to assess differences in continuous variables between groups. Differences in proportions were assessed by the w 2 -test. For statistical analysis, SPSS 14.0 for Windows was used. A P-value o0.05 was considered statistically significant.
Results
The mean AUC value for the first dose was 4690±1433 ng/ ml Â h (range 2589-8649) and 5049 ± 601 ng/ml Â h for the last dose (range 3711-6214) in the BU4 cohort. In the BU2 cohort, the mean AUC measured at the first dose was 9412 ± 5064 ng/ml Â h (range 2164-31167), while the mean AUC observed in the last dose was 11290 ± 3356 ng/ml Â h (range 6740-24154).
Veno-occlusive disease was diagnosed in 14 patients: seven in the BU4 cohort and seven in the BU2 cohort. The mean AUC in patients with VOD was 5601±1107 ng/ ml Â h (range 3329-6485) in the BU4 cohort. In the BU2 cohort, mean AUC was 12486 ± 5240 ng/ml Â h (range 9078-24154). The incidence of VOD was not different for the two BU regimens.
The two populations were divided in three groups: above-, within-and below-target. In the BU4 cohort, AUC was below target value in 19 patients, within target values in seven patients and above target values in 11 patients in the first dose, while in the last dose the number of patients was 9, 18 and 10, respectively. The corresponding frequencies in the BU2 cohort were 21 below target, four within target area and 10 patients above target in the first dose, while in the last dose the frequencies were 7, 11 and 14, respectively. No difference between AUC (expressed as the mean AUC during 4 days treatment and corrected for dose adjustment) and the incidence of VOD, relapse or TRM was observed (Figure 1 ) in the studied populations. No correlation between VOD and disease could be observed. Characteristics of patients with VOD are specified in Table 2 .
No patients died from VOD. One patient with a severe biphasic VOD underwent a liver transplantation from the same donor as the bone marrow donor and is presently well 3 years after her bone marrow and liver transplantation. 19 Two patients with VOD relapsed in the BU4 cohort and no patient with VOD in the BU2 cohort. One patient with VOD died from transplant related mortality (TRM) in the BU4 cohort and four in the BU2 cohort (CMV infection, lung bleeding and pulmonary hypertension).
Fifteen patients died in the BU4 cohort, eight from relapse of the malignant disease, two from their initial metabolic disease and five from TRM. In the BU2 cohort 11 patients died, five from relapse of their malignant disease, one from the initial metabolic disease and five from TRM. Six of eight relapses in the BU4 group and three of five in the BU2 group occurred in patients with an AUC below target. The differences in TRM and relapse between the two groups were not statistically significant.
The estimated OS at 5 years was 52.4 ± 8.8% in the BU4 cohort (median follow up 45 months) and 65.0±8.2% in the BU2 cohort (median follow up 30.3 months). Estimated DFS at 5 years was 55.6 ± 8.3% in the BU4 cohort and 65.7±8.0% in the BU2 cohort. No significant difference in OS or DFS was observed between the two cohorts.
No difference in the incidence of acute or chronic graftversus-host disease (GVHD) was noted between the two study groups. In the BU4 cohort, acute GVHD was observed in 14 patients and cGVHD in four patients. In the BU2 cohort the corresponding numbers for aGVHD was six patients and cGVHD in eight patients.
Discussion
BU is an important drug used in the preparative regimen for patients undergoing SCT. BU pharmacokinetics have cohort. The figure shows the mean AUC in all patients in the two study populations. The target value of AUC in the BU2 population (serie 1, in white) is at 9600-11 000 ng/ml Â h and in the BU4 population (serie 2, in grey) is at 4800-5500 ng/ml Â h. The patient groups are characterized as follows: (1) AUC in patients who were alive at the follow-up date, (2) AUC in patients diagnosed with VOD, (3) AUC in patients who suffered relapse of their disease, (4) AUC in patients who died from transplant-related complications. Abbreviations: AUC ¼ area under the curve; VOD ¼ venoocclusive disease. Age at transplantation is expressed in years and AUC as expressed in ng/ml Â h. Target value for AUC in the BU4 population was 4800-5500 ng/ ml Â h and in the BU2 population 9600-11 000 ng/ml Â h.
been described by many investigators. Many authors have also reported the high inter-and intra-patient variability in BU kinetics. [3] [4] [5] [6] [7] [8] [9] Exposure to BU has been correlated with both graft failure and TRM. However, several studies have shown that BU levels at the steady-state level should not be below 600 ng/ml (Css), which is equivalent to an AUC of 3600 ng/ml Â h, because of the high risk of engraftment failure. 10 Other studies recommended maximum Css levels of 900 ng/ml, which is equivalent to 5400 ng/ml Â h to minimize the transplantation-related toxicity.
In the present study, the patients treated with BU 1 mg/ kg four times daily had an AUC 5050 ng/ml Â h, which corresponds to Css of 840 ng/ml. This concentration is in agreement with values reported in previous studies. Patients treated with BU 2 mg/kg twice daily had a mean AUC of 11 290 ng/ml Â h. We were unable to find any differences in clinical outcome as the incidence of VOD, relapse of malignant disease, TRM or incidence of GVHD between the two studied cohorts.
Veno-occlusive disease occurs with a frequency of 5-40% in patients who receive 16 mg/kg oral BU-based preparative regimens. The incidence varies according to overall intensity of the conditioning regimen and therapy before transplantation. 20, 21 Various studies have shown an association between AUC of BU and the incidence of hepatic VOD. [13] [14] [15] This is not the only risk factor for VOD though; various reports confirm the effect of other drugs such as CY on sinusoidal endothelial cells and hepatocytes. 22 A small number of reports on accidental BU overdosage did not show occurrence of VOD in patients having received very high doses of BU. [23] [24] [25] The overall AUC seems to be more relevant for BU toxicity rather than peak levels, and drugs such as CY and melphalan, as well as total body irradiation, are also associated with high incidence of VOD. 26 Liver damage due to drugs and/or infections before SCT increases the incidence of VOD.
In the present study, AUC of BU was determined by a limited sampling model that is well established. 8 No correlation between high AUC and presence of VOD was detected in either of the two study cohorts. However, these cohorts contain a limited number of patients and more studies are warranted to determine the therapeutic window of BU.
Dose reduction can reduce the risk of VOD, but an increased risk of relapse with low concentrations of BU has been reported. 10, 11 A strong correlation between graft rejection and low BU concentration has also been reported. 12 In our small series, no such correlation between AUC of BU and relapse or graft rejection was observed.
BU is conventionally used at a dose of 1 mg/kg for 16 doses in myeloablative conditioning. This is a wellestablished regimen that has been used for many years in many centres. Administration of the oral formula is associated with high interpatient but also intrapatient variability that can be linked to erratic intestinal absorption, variable hepatic metabolism, circadian rhythm, genetics, diagnosis, drug-drug interaction and age. For best absorption, tablets are to be taken on empty stomach, making oral nutrition difficult during BU administration. Administration twice daily is therefore a more comfortable routine for the patient.
Intravenous (i.v.) BU has partly solved problems associated with oral administration like the variability in gastric absorption and variations in time to maximum drug concentrations. 27, 28 Still, some variability in AUC between patients is observed even with the i.v. formula, and the i.v. formula is costly and not yet available in all countries.
We conclude that the administration of oral BU at the dose of 2 mg/kg twice daily for a total of eight doses is a safe alternative to the standard regimen given as 1 mg/kg four times a day for 16 doses. A regimen consisting of fewer doses of oral medication is generally better tolerated by children and is easier to administer.
